Cochlear Protection by Local Insulin-Like Growth Factor-1 Application Using Biodegradable Hydrogel

Iwai, Koji; Nakagawa, Takayuki; Endo, Tamao; Matsuoka, Yoshinori; Kita, Tomoko; Kim, Taesoo; Tabata, Yasuhiko; Ito, Juichi

doi:10.1097/01.mlg.0000200791.77819.eb

Cited by 110 publications

(72 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also a recognized neuroprotective agent [9]. IGF-I passes through the blood-brain barrier [4], and studies have shown that brain injury may be prevented by systemic administration of human IGF [9].…”

Section: Discussionmentioning

confidence: 99%

“…However, the various studies did not diVerentiate between hearing loss of conductive, cochlear and retrocochlear origin. In studies of animal model protective drugs, local treatment with recombinant human -I (rhIGF-I) led to signiWcant protection from noise trauma [9]. Possible explanations for the eVect of IGF-I on hearing include rescue of hair cells from apoptosis and inhibition of apoptosis by downregulation of pro-apoptotic gene expression [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cochlear hearing loss in patients with Laron syndrome

Attias

Zarchi

Nageris

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The aim of this prospective clinical study was to test auditory function in patients with Laron syndrome, either untreated or treated with insulin-like growth factor I (IGF-I). The study group consisted of 11 patients with Laron syndrome: 5 untreated adults, 5 children and young adults treated with replacement IGF-I starting at bone age <2 years, and 1 adolescent who started replacement therapy at bone age 4.6 years. The auditory evaluation included pure tone and speech audiometry, tympanometry and acoustic reflexes, otoacoustic emissions, loudness dynamics, auditory brain stem responses and a hyperacusis questionnaire. All untreated patients and the patient who started treatment late had various degrees of sensorineural hearing loss and auditory hypersensitivity; acoustic middle ear reflexes were absent in most of them. All treated children had normal hearing and no auditory hypersensitivity; most had recordable middle ear acoustic reflexes. In conclusion, auditory defects seem to be associated with Laron syndrome and may be prevented by starting treatment with IGF-I at an early developmental age.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cochlear hearing loss in patients with Laron syndrome

Attias

Zarchi

Nageris

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…It is well known that insulin-like growth factor (IGF)-1 suppresses the apoptosis of nerve cells. Controlled release of IGF-1 from the gelatin hydrogel inhibited the ageing of acoustic nerve, resulting in suppressed deterioration of hearing hardness (Iwai et al 2006). This IGF-1 treatment has been started clinically to demonstrate good therapeutic efficacy (table 2).…”

Section: Clinical Aspects Of Tissue Engineering-based Tissue Regeneramentioning

confidence: 99%

Biomaterial technology for tissue engineering applications

Tabata

2009

J. R. Soc. Interface.

Self Cite

302

197

View full text Add to dashboard Cite

Tissue engineering is a newly emerging biomedical technology and methodology to assist and accelerate the regeneration and repairing of defective and damaged tissues based on the natural healing potentials of patients themselves. For the new therapeutic strategy, it is indispensable to provide cells with a local environment that enhances and regulates their proliferation and differentiation for cell-based tissue regeneration. Biomaterial technology plays an important role in the creation of this cell environment. For example, the biomaterial scaffolds and the drug delivery system (DDS) of biosignalling molecules have been investigated to enhance the proliferation and differentiation of cell potential for tissue regeneration. In addition, the scaffold and DDS technologies contribute to develop the basic research of stem cell biology and medicine as well as obtain a large number of cells with a high quality for cell transplantation therapy. A technology to genetically engineer cells for their functional manipulation is also useful for cell research and therapy. Several examples of tissue engineering applications with the cell scaffold and DDS of growth factors and genes are introduced to emphasize the significance of biomaterial technology in new therapeutic and research fields.

show abstract

“…After 1 week, animals implanted with BDNF-containing collagen hydrogels had significantly lower (improved) electrically-evoked auditory brainstem response thresholds, significantly higher density of surviving SGNs, and perilymph levels of BDNF over 100 times higher than control animals treated with saline Ito et al, 2005). Both collagen-glutaraldehyde hydrogels and gelatin hydrogels have been used to deliver recombinant human IGF-1 to the inner ear to prevent noise-induced damage (Iwai et al, 2006;Lee et al, 2007). Animals with these gels had lower auditory brainstem response thresholds and higher SGN survival than animals that received control gels.…”

Section: Hydrogelsmentioning

confidence: 96%

Localized cell and drug delivery for auditory prostheses

et al. 2008

View full text Add to dashboard Cite

Localized cell and drug delivery to the cochlea and central auditory pathway can improve the safety and performance of implanted auditory prostheses (APs). While generally successful, these devices have a number of limitations and adverse effects including limited tonal and dynamic ranges, channel interactions, unwanted stimulation of non-auditory nerves, immune rejection, and infections including meningitis. Many of these limitations are associated with the tissue reactions to implanted auditory prosthetic devices and the gradual degeneration of the auditory system following deafness. Strategies to reduce the insertion trauma, degeneration of target neurons, fibrous and bony tissue encapsulation, and immune activation can improve the viability of tissue required for AP function as well as improve the resolution of stimulation for reduced channel interaction and improved place-pitch and level discrimination. Many pharmaceutical compounds have been identified that promote the viability of auditory tissue and prevent inflammation and infection. Cell delivery and gene therapy have provided promising results for treating hearing loss and reversing degeneration. Currently, many clinical and experimental methods can produce extremely localized and sustained drug delivery to address AP limitations. These methods provide better control over drug concentrations while eliminating the adverse effects of systemic delivery. Many of these drug delivery techniques can be integrated into modern auditory prosthetic devices to optimize the tissue response to the implanted device and reduce the risk of infection or rejection. Together, these methods and pharmaceutical agents can be used to optimize the tissue-device interface for improved AP safety and effectiveness.

show abstract

Cochlear Protection by Local Insulin-Like Growth Factor-1 Application Using Biodegradable Hydrogel

Abstract: These findings demonstrate that local IGF-1 application through the biodegradable hydrogel has the potential for protection of cochleae from noise trauma.

Cited by 110 publications

References 17 publications

Cochlear hearing loss in patients with Laron syndrome

Cochlear hearing loss in patients with Laron syndrome

Biomaterial technology for tissue engineering applications

Localized cell and drug delivery for auditory prostheses

Contact Info

Product

Resources

About